Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Serum autoantibodies to cancer/testis antigens (CTAs) are key biomarkers of antitumor immunity.
• Current detection methods face challenges with recombinant CTA protein aggregation.
• Multiplexed detection is crucial for assessing immune status and monitoring therapy responses.

Purpose of the Study:

• To develop a quantitative, multiplexed assay system for detecting serum autoantibodies to CTAs.
• To validate the assay's performance using positive controls and clinical samples.
• To evaluate the utility of anti-CTA autoantibody monitoring in cancer immunotherapy.

Main Methods:

• Utilized cysteine residue-specific S-cationization to prepare water-soluble, full-length CTAs.
• Developed a multiple S-cationized antigen-immobilized bead array (MUSCAT) system with Luminex technology.
• Employed rabbit polyclonal antibodies as positive controls for assay validation.

Main Results:

• The MUSCAT assay successfully detected immobilized and endogenous CTAs.
• Assay results were confirmed by rabbit polyclonal antibodies, showing dynamic ranges.
• Autoantibody responses in a gene therapy trial correlated with clinical outcomes, with upregulation preceding tumor regression.

Conclusions:

• The MUSCAT assay provides a quantitative method for monitoring anti-CTA autoantibody biomarkers.
• This system is valuable for evaluating the cancer-immunity cycle and cancer immunotherapy.
• A quality-certified monitoring system can significantly aid in developing and assessing novel cancer therapies.